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Conservative treatment 
of invasive bladder 
cancer
In the present article, we review the most rel-
evant literature on radiochemotherapy treatments 
for infiltrative transitional-cell bladder carcinoma, 
and we show evidence that bladder preservation is 
a safe approach—as effective as the current “gold 
standard”—that should be considered as an attractive 
therapeutic option for selected patients.
2.  METHODS
We undertook a comprehensive search of the m e d l i n e  
and PubMed databases using the descriptors “blad-
der cancer,” “radiotherapy,” “bladder conservation,” 
“chemoradiation,” and “chemotherapy.” Only papers 
in the English language from large reported series 
that included patients who were deemed fit for sur-
gery were reviewed. Papers reporting on patients 
who did not systematically undergo t u r b t  followed 
by chemoradiation 10–12, on a relatively small number 
of patients 13–16, or on patients who received unusual 
chemotherapy regimens (protracted venous 17 or 
intra-arterial 18–27 infusion) were not included in 
the review.
3.  RESULTS
3.1  Cystectomy
Radical cystectomy is considered by most urolo-
gists to be the “gold standard” treatment for muscle-
invasive transitional-cell carcinoma of the bladder. 
This surgery consists of the cystectomy itself, often 
accompanied by a prostatectomy (in some patients a 
prostate-sparing technique is possible) or anexohys-
terectomy, lymphadenectomy, and urinary diversion. 
Options for urinary diversion include ileal conduit, 
continent cutaneous reservoir, and orthotopic neo-
bladder 2,28,29. An orthotopic neobladder consists in 
reconnecting the ureters to an intestinal segment that 
is connected to the urethra. This procedure avoids the 
stoma in the abdominal wall required with the ileal 
conduit and the continent cutaneous reservoir.
The use in recent decades of orthotopic neo-
bladder has encouraged most urologic surgeons to 
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1.  INTRODUCTION
Urinary bladder cancer is the ninth most frequent 
cancer worldwide, accounting for 2.1% of all cancer 
deaths 1. Most of these cancers (65%–70%) are su-
perficial at presentation and are typically managed 
conservatively. Bladder tumours are staged accord-
ing to the depth of invasion. The main distinction, 
in terms of treatment and prognosis, is whether the 
disease invades the muscular layer of the bladder 
wall. In general, non-infiltrating tumours are treated 
with transurethral resection of the bladder tumour 
(t u r b t) plus intravesical instilled treatments (bacille 
Calmette–Guérin or chemotherapy); infiltrating 
tumours are treated in a more aggressive way.
The most commonly accepted standard local treat-
ment for muscle-infiltrating tumours remains radical 
cystectomy with pelvic lymph node dissection 2. Since 
the late 1980s, several centers have used bladder-pre-
serving strategies, combining radiotherapy (r t ) and che-
motherapy as an alternative to radical cystectomy 3–9.
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advocate cystectomy as the preferred treatment. 
However, not all patients are candidates for such 
a procedure. In a large series from the University 
of Southern California, Stein et al. 2 reported that, 
of 1054 surgical patients between 1971 and 1987, 
only 38% had an orthotopic diversion performed. 
The series included many patients treated before 
the neobladder procedure was available. If patients 
treated only after 1987 (when neobladder became 
the standard for selected men) are considered, 63% 
underwent the procedure, and if the analysis is 
further limited to patients treated after 1992, when 
neobladder became the standard for women as well, 
then 69% of patients received a neobladder.
In a urinary diversion consensus meeting con-
vened by the World Health Organization and the 
Société Internationale d’Urologie 30, pooled data 
from 8 centers involving 7129 patients showed that 
only 47% had undergone an orthotopic diversion. Ex-
cluding the two series that included patients treated 
before 1986, a total of 53% of patients underwent 
orthotopic urinary diversion. Thus, not all patients 
are eligible for orthotopic urinary diversion, limit-
ing the number of patients that will keep the ability 
to void per urethra. The inability to obtain a nega-
tive margin in the urethra in a male patient is an 
absolute contraindication for the procedure; relative 
contraindications include an incapacity to perform 
self-catheterization if the need arises, renal insuffi-
ciency, and hepatic dysfunction 28.
The report from the University of Southern 
California is probably one of the largest published 
radical cystectomy series in patients harbouring 
bladder cancer 2. Their results should be considered 
the “gold standard” against which other treatments 
should be compared. This large series of 1054 patients 
excluded 112 patients with inoperable disease or those 
who, after the surgery, were found to have positive 
macroscopic (gross) margins. In that series, which in-
cludes 39% pT1 or lesser tumours, the recurrence-free 
survival rates at 5 and 10 years were 68% and 66% 
respectively, and the 5- and 10-year overall survival 
rates were 60% and 43% respectively. Although not 
stated by the authors, the calculation of the disease-
free survival rates may have censored patient deaths 
from other causes. Such censoring would explain 
the disease-free survival rate being higher than the 
overall survival rate. The local recurrence rate was 
9%, and in 23% of the patients, positive lymph nodes 
were found at the time of the operation. The surgical 
mortality rate was 3%.
3.2  Bladder Preservation Therapy
Interest has been growing in a more conservative, 
organ-preserving approach to many malignant 
tumours. The association of a limited surgery and 
radiotherapy (r t ) is the basis of most of the organ-
preservation protocols. Today, conservative treatment 
for breast, larynx, esophagus, anus, and lower rectum 
carcinomas and limb sarcomas is the standard of care 
in many oncologic centers 31.
Historically, bladder-conservative treatments, 
mostly with r t  alone 32–38, were initially used in 
patients who were not candidates for surgery. De-
spite the poorly selected population, the 5-year local 
control rate for these patients ranged between 35% 
and 45% 32,34,36, with a 5-year overall survival of 
25%–40% 33–35,37–39. Those results were considered 
inferior to the results for surgery, and therefore r t  as 
a single-modality therapy was rarely fully explored 
in a better-selected cohort of patients. A possible 
exception is the series from the Princess Margaret 
Hospital 3 in which, of 340 patients treated radically 
with r t, 131 had T2 disease without nodal involve-
ment. Of those patients, 108 received r t  alone. The 
5-year cause-specific survival without cystectomy 
for all T2 patients (including those treated using a 
combined approach) was 52%. The use of r t  alone 
as a first-line primary treatment has practically 
been abandoned.
Three randomized trials 40–42 have compared pre-
operative r t  followed by surgery against radical r t  
with cystectomy reserved for recurrent local disease. 
Only the smallest of these studies, with 67 patients 
enrolled, showed a survival benefit for immediate 
surgery 41. The other two trials did not find a statisti-
cally significant difference in overall survival between 
arms at 5 years. Two population-based studies 43,44 
also show that the survival rate is the same whether 
cystectomy is the initial treatment or whether it is 
reserved for possible recurrence after radical r t .
3.3  Trimodality Treatment: TURBT + RT 
+ Chemotherapy
Since the late 1980s, several centers have pioneered 
the bladder-preserving strategy as an alternative to 
radical cystectomy 3,5–9,45–47. This strategy is multi-
disciplinary. It includes as thorough as is possibly safe 
t u r b t , followed by r t  combined with chemotherapy, 
targeting patients with nonmetastatic muscle-invasive 
bladder cancer. Among several institutions using this 
approach, three have the largest experience, and their 
treatment methods and results are reviewed here. The 
Radiation Therapy Oncology Group (r t o g ) has also 
actively participated in the development of novel con-
servative treatments in the multi-institutional setting, 
and its experience is also reviewed.
The University of Erlangen 7, the Massachusetts 
General Hospital (m g h ) 9, and the University of 
Paris 5 developed protocols that are based on similar 
therapeutic approaches. According to their studies, 
a complete response to an initial treatment consisting 
of t u r b t  followed by irradiation plus chemotherapy 
selects patients whose tumour is likely to be controlled 
by a bladder-sparing approach. After several weeks 
of radiochemotherapy, a cystoscopy is performed to RENE et al.
Cu r r e n t On C O l O g y —VO l u m e  16, nu m b e r 4
38
assess the response rate. If residual disease (macro- or 
microscopic) remains, the intent of bladder preserva-
tion is aborted, and the patient is considered for a 
cystectomy. On the other hand, if a complete response 
is achieved, then a consolidative phase of radiochemo-
therapy is carried out for few more weeks, for a full 
course of radiochemotherapy.
The University of Erlangen has probably the lar-
gest experience in bladder preservation treatment for 
bladder cancer 7,48. Their multimodality experience 
covers a span of more than 20 years. In their initial 
work, r t  was given alone; since 1985, chemother-
apy has been given concomitantly with r t . The first 
chemotherapeutic agent used was carboplatin, later on 
replaced by cisplatin. Finally 5-fluorouracil (5f u) was 
added to cisplatin. A total of 415 patients with high-
risk T1 (grade 3, associated carcinoma in situ, multiple 
recurrences, or tumour size greater than 5 cm) to T4 
bladder cancer were treated. The treatment starts with 
t u r b t ; 4 weeks later, radiochemotherapy is given. A 
dose of 45–54 Gy is administered to the bladder and 
pelvic nodes, and then the whole bladder is boosted to 
a dose that depends on the completeness of the initial 
t u r b t . If the procedure was complete, the bladder is 
boosted to 55.8 Gy; if micro- or macroscopic disease 
is present after t u r b t , the bladder is boosted to a total 
dose of 59.4 Gy. The daily dose is 1.8 Gy. Six to eight 
weeks after completion of treatment, response is as-
sessed by cystoscopy. If the response is incomplete, 
cystectomy is indicated.
In 2002, Shipley et al. 9 published the m g h  ex-
perience in bladder preservation therapy, called 
trimodality therapy (t m t). Clinical stages T2–T4a 
were included. Patients were excluded if they had 
pathologically proven positive nodes or hydroneph-
rosis (an exclusion criterion that was introduced in 
1993). Over 11 years, 190 patients were enrolled in 
five different protocols of t m t  with a median follow 
up of 6.7 years. All m g h  protocols had in common 
the use of an as-complete-as-possible t u r b t, con-
comitant cisplatin-based radiochemotherapy, and the 
recommendation of cystectomy if complete response 
was not achieved with the induction phase. Upon 
a complete response from the induction phase, a 
second (consolidation) phase was given to adminis-
ter a curative dose of r t. The differences among the 
m g h  protocols were the use (or not) of neoadjuvant 
or adjuvant chemotherapy, the addition (or not) of 
other chemotherapeutic agents to cisplatin during 
r t, and the radiation fractionation schedule. These 
pilot studies were the foundation on which the r t o g  
developed several investigative protocols.
In 1993, Housset et al. 5 published the prospect-
ive experience in bladder preservation treatment of 
the Hôpital Necker in Paris. That protocol included 
54 patients, 42% of whom had an abnormal intra-
venous pyelogram and 7% of whom had positive 
pelvic nodes by computed tomography scan. As in 
the Boston experience, the protocol consisted of 
t u r b t  followed by radiochemotherapy. The drugs 
used were 5f u and cisplatin, and the r t  was given in 
a bi-fractionated split course. On days 1, 3, 15, and 
17, 3 Gy were administered to the pelvis on a twice-
daily schedule. Chemotherapy was given on days 1, 
2, 3, and 15, 16, 17. Six weeks later, a cystoscopy 
with deep biopsies was performed to define the next 
course of treatment. If residual tumour was present 
at cystoscopic assessment, radical surgery was then 
carried out. Patients achieving a complete response 
would continue with radiochemotherapy or could 
undergo a cystectomy. If the patient continued r t , 
a similar scheme of radiochemotherapy was given 
on days 64, 66, 78, and 80. The only differences in 
this consolidation phase were that the dose per frac-
tion was reduced to 2.5 Gy twice daily and only the 
bladder volume was treated. Interestingly, Housset et 
al. 5 reported that the first 18 patients who achieved a 
complete response with induction radiochemotherapy 
and subsequently underwent a planned cystectomy 
evidenced a complete response (by pathology) in 
the bladder; moreover, all the resected pelvic nodes 
were also pathologically negative. Updated results 
of this original publication with 120 patients were 
presented in 1997 49.
Despite the fact that the foregoing protocols have 
the same objective (bladder preservation) and present 
several similarities, they have distinct differences that 
are worth mentioning. Shipley’s group in Boston 9 
and the University of Paris 5 opted for an induction 
treatment, after which the patient is scoped so that a 
decision can be made between completing a radical 
dose of radiochemotherapy or undergoing a cystec-
tomy if residual disease is found. The University of 
Erlangen 7 policy is to give the full combined treat-
ment up front and only then to assess cystoscopic-
ally, performing a cystectomy in the case of residual 
disease (Figure 1).
f i g u r e  1   The Massachusetts General Hospital (m g h ) and University 
of Erlangen therapeutic algorithms. t u r b t = transurethral resection 
of the bladder tumour; r t = radiation therapy; C h t  = chemotherapy; 
n e d  = no evidence of disease; f u = follow-up.PRESERVATION THERAPY IN BLADDER CANCER
39
Cu r r e n t On C O l O g y —VO l u m e  16, nu m b e r 4
From a theoretical viewpoint, each approach has 
advantages. Giving the full treatment up front avoids 
a split course of radiotherapy that could reduce the 
chance of disease control; the Boston and Paris ap-
proaches “prioritize” the fact that, in nonresponders, 
surgery would not be delayed and would be carried 
out after a lower dose of radiation, reducing the prob-
ability of complications (preoperative dose). On the 
other hand, the Erlangen approach gives more time 
to “slow-responding” tumours to achieve a complete 
response, theoretically reducing the number of un-
necessary cystectomies.
Another major difference between the protocols 
is the radiotherapy fractionation scheme used. The 
University of Erlangen uses a standard fractionation 
scheme; the University of Paris uses a bi-fractionated 
split course; and the Boston group has used several 
protocols, changing fractionation schemes over the 
years. Interestingly, none of the protocols has proved 
to be superior.
The r t o g  has carried out several investigative 
protocols exploring conservative treatment of blad-
der cancer. The r t o g  85-12 protocol 50 was the first 
trial developed. It consisted of an induction phase 
combining r t  with cisplatin (100 mg/m2 on days 1 
and 22). Complete responders received additional 
r t  and a third dose of cisplatin. Encouraging results 
of this first study led to several others. The r t o g  
88-02 protocol 51 was a phase ii trial that evaluated 
the toxicity of adding neoadjuvant methotrexate, 
cisplatin, and vinblastine (m c v ) to the combined 
treatment. Treatment was well tolerated, and a ran-
domized phase iii trial followed (r t o g  89-03) to as-
sess the efficacy of neoadjuvant m c v  52. That study 
was stopped early, with only 123 patients enrolled, 
because of slow accrual and excessive toxicity in the 
m c v  arm, including 4 treatment-related deaths. The 
addition of neoadjuvant m c v  did not show any ben-
efit in terms of complete response rate, overall 
survival, or bladder preservation rate, and so the 
strategy was abandoned. The next protocol (r t o g  
95-06) evaluated hypofractionated radiotherapy 53. 
The regimen tested was the accelerated and hypof-
ractionated scheme developed by the University of 
Paris 5. Overall survival was encouraging: 83% at 
3 years, with 66% of patients surviving this period 
with an intact bladder. A 21% grade 3–4 genitouri-
nary toxicity rate was a concern. Protocol 97-06 
evaluated hyperfractionated radiotherapy (twice 
daily) with concomitant cisplatin (20 mg/m2 the first 
3 days of each treatment week) followed by adjuvant 
m c v  (3 cycles) 54. Protocol r t o g  99-06 also evalu-
ated hyperfractionated r t, but at a slightly lower 
daily dose. The main and novel changes in that study 
were the addition of paclitaxel to the concurrent 
cisplatin and the introduction of gemcitabine plus 
cisplatin in the adjuvant setting. A report in abstract 
form from 2005 55 shows an excellent complete re-
sponse rate of 87% with 32% grade 3–4 toxicity 
during r t  and 74% during adjuvant chemotherapy. 
Protocol r t o g  02-33, which aims to assess the effi-
cacy of paclitaxel compared with 5f u, both given 
concomitantly with cisplatin and r t, has recently 
closed to accrual. Finally, an ongoing study (r t o g  
05-24) is designed to test if the addition of trastu-
zumab to paclitaxel is beneficial in patients with 
overexpression of the human epidermal growth fac-
tor receptor (h e r 2/neu). That trial is intended for 
non-cystectomy candidates.
To our knowledge, the only randomized trial 
that compared r t  with r t  plus chemotherapy for in-
vasive bladder cancer was the study carried out by 
the National Cancer Institute of Canada 4. Their trial 
randomized 99 patients with muscle-invasive blad-
der tumours to a preoperative dose of radiotherapy 
with or without cisplatin. A radical cystectomy or a 
radiotherapy boost to the bladder was then done. This 
second “choice” was not randomly assigned. Pelvic 
progression-free survival was significantly increased 
in the cisplatin arm (5-year pelvic relapse-free sur-
vival: 40% vs. 59%; p = 0.036). This reduction in 
the risk of pelvic failure was not limited to patients 
treated with definitive r t, but was also seen in patients 
who underwent cystectomy. In patients who opted for 
conservative treatment, complete clinical response 
at cystoscopy after the induction phase and bladder 
preservation rate at last follow-up were more often 
seen in the combined arm. Of patients who were ran-
domized to the combined arm and who underwent a 
cystectomy, 54% presented no evidence of invasive 
disease in the removed bladder, as compared with 
40% in the r t  alone arm (p = nonsignificant). A 
trend was noted for increased overall survival and 
decreased rate of failure of any type in the cisplatin 
arm, but because of the small number of patients, 
pelvic progression-free survival was the only variable 
that reached statistical significance.
4.  DISCUSSION
4.1  Survival and Local Control
Survival in modern bladder preservation series 
has improved over that in older publications, when 
chemotherapy was not given concomitantly with 
radiotherapy 7,9,33–35,37–39. The current 5-year overall 
survival ranges from 49% to 67% 7,9,50–52,56. At 10 
years, overall survival is 31%–36% 7,9. Figure 2 shows 
overall survival curves from three bladder preserva-
tion protocols 7,47,52 and from one of the largest surgi-
cal series 2. Despite small differences in design, the 
conservative bladder studies show similar survival 
outcomes. The survival curve from the cystectomy 
series includes the 39% of patients with pT1 or lesser 
disease. If patients with only muscle-invasive disease 
are analyzed, the 5- and 10-year overall survival rates 
for cystectomy are 48% and 32% respectively—
identical to the results achievable with t m t .RENE et al.
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In Erlangen 7, the first patients were treated with r t  
alone; chemotherapeutic agents were then added con-
comitantly with radiotherapy. The complete response 
and the 5-year overall survival rates improved with 
each change (Table i). Whether these improvements 
are truly related to the newer approaches or to other 
factors such as patient selection (larger proportion of 
T1 tumours in the later series), stage migration, or a 
shorter follow-up, the effect on outcomes remains to 
be determined.
Approximately 12%–40% of patients will not 
achieve a complete response with t m t  and will be con-
sidered for an immediate cystectomy 5,7,9,48–51,53–56. 
Among the complete responders, approximately one 
third (14%–50%) will fail locally. Approximately 
60% of local failures are superficial; the remaining 
40% are muscle-invasive 5,7,9,51–53. Most of the super-
ficial recurrences are managed in a conservative way 
(see the “Recurrences After Bladder Preservation” 
subsection). Overall, the 5-year survival rate with an 
intact bladder ranges from 38% to 51%, representing 
a rate of approximately 80% bladder preservation in 
long-term survivors 7,9,51–56.
Table ii summarizes the characteristics and results 
of various series. The highest complete response rates 
are from the two series that combined cisplatin with 
another chemotherapeutic agent concomitantly with 
radiotherapy. Both [the University of Erlangen 7,48, 
combining cisplatin with 5f u (Table i), and r t o g  99-
06 55, combining cisplatin plus paclitaxel (Table ii)] 
report a similar complete response rate of 87%. These 
two series have included more patients with early 
disease than other series have (90% of T2 tumours in 
the r t o g  99-06 55 study, and 48% T1 in the Erlangen 
series 48), and this cohort composition could explain, 
in part, the reason for the higher complete response 
rates. Notably, other series using multidrug regimens 
combined with hypofractionated r t  did not achieve 
the same complete response rates 5,49,53.
3.5  Prognostic Factors
Several variables have been correlated with survival 
and bladder preservation rates in organ-preservation 
treatments for bladder cancer. Tumour stage, as ex-
pected, affects local control and survival 3,7,9,50,56. 
The complete response rate for T2 tumours ranges 
from 71% to 88% and for T3–4 tumours, from 57% 
to 72% 7,9,50,56. Recently, Weiss et al. 48 published a 
series of 112 patients treated with r t  and concomitant 
cisplatin/5f u, reporting freedom from local relapse 
at 5 years of 66% for T1 and 51% for T2–4. In the 
Boston experience 9, the 5-year overall survival for 
T2 tumours was 62%, and for T3–4 tumours, it was 
47%. The 5-year disease-specific survival was 74% 
for T2 and 53% for T3–4. The Erlangen series 7, 
with 415 patients, reported 5- and 10-year overall 
survival rates of 75% and 51% respectively for T1 
tumours. Those rates decreased to 56% and 32%, 
44% and 26%, and 17% and 9% for T2, T3, and T4 
tumours respectively. In the multi-institutional r t o g  
protocol 85-12 50, a 4-year overall survival of 64% for 
T2 and 24% for T3–4 tumours was observed. In an 
unselected group of patients, Chung et al. 3 reported 
overall survival for T2 tumours of 43% and 27% at 
5 and 10 years respectively. These same figures for 
T3–4 disease dropped to 16% and 7% respectively 
(p < 0.01). In our opinion, the two major reasons for 
the poor outcomes in this last series were the unse-
lected nature of the patients assigned to treatment 
(more than 25% were not medically fit for surgery) 
and, most importantly, the 73% of patients treated 
without concomitant chemotherapy. This same study 
also showed that, in a subset of T2N0M0 patients, 
the local relapse-free rate was significantly higher if 
the tumour was 2 cm or smaller, indicating that not 
only T stage, but also the actual size of the tumour 
are important predictive factors affecting the rate of 
disease recurrence.
The presence of hydronephrosis at diagnosis has 
been shown by some studies to significantly affect 
f i g u r e  2   Overall survival curves from the Massachusetts General 
Hospital 9, the University of Erlangen 7, the Radiation Therapy Oncol-
ogy Group (r t O g ) 89-03 52, and the University of Southern California 2 
studies. Notably, in the cystectomy series from the University of 
Southern California, 39% of the patients had pT1 or lesser disease, 
which may explain the apparent better outcome as compared with 
bladder preservation protocols. Trimodality therapy series using 
various approaches yield similar 5-year overall survival rates.
t a b l e  i   The 5-year overall survival and complete response rates 
from the University of Erlangen based on changes in therapeutic 
approaches over the years 7,48
Treatment Overall
survival
Complete
response
(%) (%)
r t  alone 40 61
r t +carboplatin 45 66
r t +cisplatin 62 82
r t +cisplatin+5f u 65 87
r t  = radiation therapy; 5f u = 5-fluorouacil.PRESERVATION THERAPY IN BLADDER CANCER
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complete response rates. According to the Boston 
experience 9, in the presence of hydronephrosis, the 
complete response rate was 37% as compared with 
68% when hydronephrosis was absent. This obser-
vation led to the incorporation of hydronephrosis as 
an exclusion criterion in their subsequent bladder 
preservation protocols. Other studies 36,52 also found 
a significant relationship between a poor complete 
response rate and the presence of ureteral obstruc-
tion. Hydronephrosis has also been associated with a 
significantly increased risk of distant metastasis 51.
Rodel et al. 7 found a statistically significant as-
sociation between the completeness of the t u r b t  and 
both higher complete response rate and improved 
overall survival. The complete response rate in pa-
tients with a complete t u r b t  was 90%, decreasing 
to 77% in patients with microscopic residual disease 
after t u r b t and to 54% if macroscopic residual 
disease was present. The 10-year overall survival 
rates in R0, R1, and R2 were 50%, 33%, and 18% 
respectively. In a series of 122 patients, Perdona et 
al. 56 also observed the same detrimental effect of 
an incomplete t u r b t . However, in other studies, the 
completeness of the t u r b t did not significantly affect 
the complete response rate or survival. Interestingly, 
however, those studies did find that the survival rate 
with an intact bladder was higher in patients with a 
complete, as compared with an incomplete, t u r b t 
(r t o g  89-03: 38% vs. 64%; p = 0.06; Boston: 29% 
vs. 50%; p < 0.01) 52,57.
The presence of carcinoma in situ (c i s ) associated 
with invasive disease in the bladder is another variable 
that has been associated with decreased local control 
rates. The Princess Margaret Hospital experience 3 
shows a significant increase in local relapse rates in 
patients with associated c i s . The local relapse-free 
rate was 61% if c i s  was absent against 29% if present. 
The 5-year overall and cause-specific survival rates 
were also decreased in the presence of c i s . On the 
other hand, other series 7,56 did not find a significant 
relationship between complete response rate or sur-
vival and the presence of c i s . In a consensus meeting 
convened by the Société Internationale d’Urologie 58, 
the radiotherapy panel indicated that the presence 
of extensive c i s  in association with muscle-invasive 
bladder cancer increases the risk of a superficial 
recurrence after t m t , and that these patients have an 
increased risk of requiring a cystectomy for a future 
recurrence. Considering that the overall survival 
rate in patients that require a salvage cystectomy is 
similar to that in patients that never recur, the panel 
concluded that the presence of c i s  is not an absolute 
contraindication to the use of t m t .
The completeness of response to induction treat-
ment is a predictive factor for metastasis, suggesting 
that non-responding tumours are intrinsically more 
aggressive and may metastasize earlier. Rodel et al. 7 
reported that freedom from distant metastasis in 
complete responders was 79% and 70% at 5 and 
10 years, significantly higher than in non-complete 
t a b l e  ii   Results of trimodality therapy in bladder preservation studies
Study Treatment Pts
(n)
Median
follow-up
(months)
C r
(%)
Overall survival (%) Bladder
preservation
in long-term
survivors
(%)
l r
rate
(%)
5-year 10-year 5-year
with bladder
preservation
r t o g  88-02 51 Neoadjuvant m c v  plus c–r t 91 46 75 62
(4-year)
44
(4-year)
60 50
r t o g  89-03 52 With/without neoadjuvant 
m c v  plus c–r t
123 61 59 49 38 78 43
r t o g  95-06 52 c/5f u/hypofx b i d   
split-course r t
34 29 67 83
(3-year)
66
(3-year)
79 45
r t o g  97-06 54 c/hyperfx b i d  r t  with  
adjuvant m c v
47 26 74 61
(3-year)
48
(3-year)
79
(3-year)
19
r t o g  99-06 55 c/p/hyperfx b i d  r t  with 
adjuvant g/c
47 30 87 79
(2-year)
69
(2-year)
87
(2-year)
18
University of Paris 5 c/5f u/hypofx b i d   
split-course r t
120 49 77 63 17
m g h  9 Varying protocols (see text) 190 80 64 54 36 45 83 40
University of  
   Erlangen 7
Varying protocols  
(see Table i)
415 60 72 51 31 42 82 35
Pts = patients; c r  = complete response; l r = local recurrence; r t o g  = Radiation Therapy Oncology Group; m c v  = methotrexate, cisplatin, 
vinblastine; c = cisplatin; r t  = radiation therapy; 5f u =5-fluourouracil; hypofx = hypofractionated; b i d  = twice daily; hyperfx = hyperfraction-
ated; p = paclitaxel; g = gemcitabine; m g h  = Massachusetts General Hospital.RENE et al.
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responders (52% and 48% respectively). Housset 
et al. 49 described an overall survival of 73% at 5 years 
in complete responders and 29% in non-complete 
responders (p < 0.0001). The same study also showed 
that, after achieving a complete response to induction 
radiochemotherapy, patients experienced no differ-
ence in overall survival at 5 years whether operated 
on or having completed the bladder preservation ap-
proach, suggesting that the induction radiochemo-
therapy phase is an effective and selective method 
for optimally defining patients that are good candi-
dates for ultimately preserving their bladder.
4.2  Recurrences After Bladder Preservation
The risk of developing a local recurrence after 
achievement of a complete response ranges from 14% 
to 43% at 5 years with 30%–50% of patients present-
ing a component of invasive disease 5,7,9,49,52. Most 
local recurrences appear within the first 12–24 months 
from the end of therapy, and thus patients need to be 
followed closely with repeated cystoscopies during 
this period 3,5,50,51,59,60. However, follow-up should 
not be limited to the first 2 years after treatment, 
because some series 3,59–61 report local recurrences 
as late as 5–10 years after treatment. Some of these 
patients can still be salvaged surgically.
Cystectomy is the treatment of choice for mus-
cle-invasive local recurrences, and approximately 
30%–40% of locally relapsing patients ultimately 
undergo a cystectomy 7,51,53. In the largest published 
series to date, salvage cystectomy for an invasive 
recurrence after a complete response from t m t  yields 
5- and 10-year disease-specific survival rates of 50% 
and 45% respectively 7. A non-complete response to 
t m t  appears to be associated with a poorer prognosis, 
with only 21% of patients achieving 5-year disease-
specific survival. One other large study 9 showed a 
similar disease-specific survival rate in patients who 
underwent a cystectomy for an incomplete response 
as compared with patients who were operated for a 
local muscle-invasive recurrence after a complete re-
sponse. Whether the difference between series results 
from biologic tumour behaviour or from therapeutic 
strategy remains to be determined.
One important issue related to recurrent disease is 
how to treat superficial recurrences. More than 87% of 
patients 50–53,59,60 are typically managed with a conserva-
tive approach with t u r b t , with or without intravesical 
treatment. Those remaining are treated mostly using 
cystectomy. The rate of a second local recurrence in 
conservatively treated patients ranges from 36% 60 to 
52% 59, and the risk of developing invasive disease after 
being treated conservatively for a superficial recurrence 
ranges from 0% to 19% 5,50,52,53,59,60. Those results are 
comparable to those obtained in de novo superficial tu-
mours treated in non-irradiated bladders 62. Overall, 0% 
to 31% of the patients will eventually need a cystectomy 
after developing a superficial recurrence 50–53,59,60.
In the only two studies that analyzed in detail the 
management of superficial recurrences, the develop-
ment of a superficial recurrence did not affect long-
term disease-specific or overall survival as compared 
with survival in patients that did not recur. However, 
in both studies, long-term survival with a preserved 
bladder decreased by approximately 40% 59,60. In 
other words, superficial recurrence after t m t  appears 
to be a negative prognostic factor for bladder preser-
vation, but not for survival.
4.3  Cystectomy Rate
When a bladder preservation approach is being 
considered, the patient has to be aware that ap-
proximately one third of patients will not achieve a 
complete response. An immediate cystectomy offers 
the best chance of cure if the disease is still local-
ized. Even after a complete response, compliance 
with frequent follow-up cystoscopies is of paramount 
importance, because in the case of a local recurrence, 
a cystectomy may be necessary. Overall, 20%–40% 
of patients undergo a cystectomy at some point be-
cause of incomplete response, local recurrence, or 
treatment complications. The probability of requiring 
removal of the bladder because of complications is 
0%–2% 3,5,7,9,50,51,53,56.
One concern on which many urologists base 
their opposition to bladder preservation therapy is 
the potential difficulty of performing a continent 
urinary diversion after radical doses of radiation. 
In 1998, the University of Southern California pub-
lished its experience in cystectomy with neobladder 
reconstruction in patients that had received r t  to the 
pelvis 63. In their small series of 18 cases, the com-
plication and continence rates were similar to those 
obtained in non-irradiated patients. Similar findings 
were presented in another series 64 of 37 women with 
a history of prior pelvic irradiation who underwent 
a pelvic exenteration for pelvic tumour recurrence 
or urinary diversion for vesicovaginal fistula and 
had an ileocecal continent urinary reservoir. In the 
Boston series 9, only 2 of 66 cystectomized patients 
(3%) underwent a continent urinary diversion; other 
smaller series reported rates of 21% (4/19) and even 
100% (3/3) 5,6.
4.4  Which Drug to Use?
The largest experience in radiochemotherapy-based 
organ-preservation treatments for bladder cancer is 
with cisplatin 4,5,7,9,49,56. The University of Erlangen 
studies 7 evolved by changing only the chemothera-
peutic agent, keeping unchanged the rest of the treat-
ment components. This “simple and ordered” step in 
the evolution of the protocol made it easier to evaluate 
the effect of various drugs in the outcome 65. Over 
the years, the investigators moved from r t  alone to 
chemo-r t  using a single agent, and later, to combined PRESERVATION THERAPY IN BLADDER CANCER
43
Cu r r e n t On C O l O g y —VO l u m e  16, nu m b e r 4
chemotherapy agents. The complete response rate was 
significantly enhanced by the combined approach, 
translating into improved survival rates (Table i). 
Whether the addition of 5f u truly improves results still 
needs to be confirmed. The newer regimens included 
a larger number of patients with earlier disease, and 
part of the improved outcome may be related purely 
to that factor.
Similar complete response rates to multidrug 
concomitant regimens were obtained with cisplatin–
paclitaxel in r t o g  protocol 99-06 55. In contrast to the 
German experience, the r t o g  trial used hyperfrac-
tionated r t  and also added cisplatin and gemcitabine 
in the adjuvant setting. The final results are not yet 
available, but an interim analysis 55 revealed that 
87% of patients completed the treatment per protocol 
and that the estimated 2-year survival with an intact 
bladder is 69%.
Currently, no solid data support one chemother-
apy agent over the other. Cisplatin is the agent most 
frequently used, and we believe that it is the one that 
should be considered for treating patients outside the 
setting of an investigative protocol. Based on the large 
experience of the University of Erlangen with 5f u plus 
cisplatin 7, that combination can also be considered 
for selected patients.
4.5  Quality of Life
To be considered an alternative therapy with respect 
to surgery, a bladder preservation treatment has to 
preserve a native bladder capable of performing its 
function in a normal, or almost normal, way. A review 
article by Wright and Porter 66 shows the difficulty 
in assessing quality of life (q o l ) in bladder cancer 
patients. The most disturbing symptom is probably 
incontinence. Surgical series report daytime conti-
nence rates of 70%–95%. Nighttime continence is 
more problematic, with rates of 65%–85% 28.
On the other end of the spectrum, a French Na-
tional Survey 67 study reported nighttime continence 
rates of only 17.4% in patients with neobladder and 
interference with sleep in 32% of all patients. In 
that survey, 40% of the patients had to wear at least 
one pad daily. However, 90%–95% of the patients 
were satisfied with their urinary diversion 67,68. This 
discordance between continence and satisfaction is 
probably a result of patients interpreting and eventu-
ally becoming used to their symptoms as the price to 
pay to be cured of cancer.
Zietman et al. 69 performed urodynamic tests 
and a q o l  study on long-term survivors treated with 
t m t  for infiltrative bladder cancer. Of the 71 patients 
alive at a median follow-up of 6.3 years, 68% com-
pleted a q o l  questionnaire, and 45% were tested with 
urodynamic studies. Of these patients, 75% were 
considered to have bladders with normal function. 
Five women, representing 11% of the patients, had 
to wear pads. Weiss et al. 48 analyzed 71 patients with 
a q o l  questionnaire, and 78.8% were “delighted” or 
“pleased” in terms of urinary function.
The risk of having to remove a bladder because 
of post-radiotherapy contraction is 0%–2% 9,65. The 
University of Erlangen 48,65 reported that only 2% of 
patients required a “salvage cystectomy” for “con-
tracted bladder” (grade 4) and that 9% developed a 
reduced bladder capacity (grade 3) without the need 
for surgery, despite the fact that many patients under-
went multiple t u r b t  procedures before t m t .
Zietman et al. 69 demonstrated that 54% of men 
had erections hard enough for intercourse and that 
59% were satisfied with their sex life after conser-
vative treatment. These rates compare favourably 
with a contemporary questionnaire-based study 
that reported an 87% rate of inability to maintain an 
erection after radical surgery 70. Following nerve-
sparing cystoprostatectomy, potency rates of 42% 
have been reported 71.
5.  FUTURE DIRECTIONS
The current experience with t m t  protocols are with 
conventional or three-dimensional (3-D) conformal 
r t . Intensity-modulated r t  (i m r t ) and image-guided r t  
allow for highly conformal dose delivery to target vol-
umes, with decreased dosage to normal organs at risk. 
Use of these techniques in bladder cancer patients 
may lead to further improvements in local control 
rates without increasing the risk of side effects. The 
superiority of these techniques over 3D-conformal 
r t  with respect to tumour control and side effects 
has been shown both dosimetrically and clinically 
in many studies. The use of i m r t  in bladder cancer is 
still preliminary, and further experience is obviously 
needed. However, the prospect of delivering a higher 
biologically equivalent dose (concomitant boost 
technique) or of dose escalation under conventional 
fractionation is an attractive alternative that is now 
being explored in prospective trials.
Although platinum and taxane compounds are 
now the most frequently used chemotherapy agents 
in bladder preservation studies, new promising data 
emerging from the use of gemcitabine are making that 
agent another potential drug for use in t m t . Kent et al. 6 
from the University of Michigan reported on a phase i 
trial using twice-weekly gemcitabine (27 mg/m2) 
concomitantly with conventionally fractionated r t . 
The toxicity was acceptable, and 65% of the patients 
were disease-free with a native bladder at a median 
follow-up of 43 months. In a similar phase i study 
with weekly gemcitabine and concomitant hypofrac-
tionated r t , 7 of the 8 patients were disease-free at a 
median follow-up of 19.5 months 8. These preliminary 
but encouraging results will now be tested in a ran-
domized phase ii study by the r t o g . Interestingly, the 
r t o g  will, for the first time in bladder cancer, allow 
the use of i m r t  for delivery of the r t  component. More 
than 50% of patients with invasive bladder cancer die RENE et al.
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from metastatic disease, and therefore more effective 
adjuvant systemic therapy is required to truly improve 
overall survival in these patients.
Molecular profiling is an exciting area that holds 
promise that clinical outcomes might be improved by 
identifying the mechanisms and targets associated 
with the growth of a tumour and by developing po-
tential and specific therapeutic agents. A significant 
number of laboratory and clinical investigations have 
uncovered molecular markers in bladder cancer, and 
some of these are being actively investigated.
A recent r t o g  report 72 analyzing histopatho-
logic material from four bladder preservation trials 
(r t o g  88-02, 89-03, 95-06, and 97-06) described a 
significant correlation between h e r 2/neu overex-
pression and decreased complete response rates. 
That finding led the r t o g  to develop an ongoing 
trial (r t o g  05-24) in which patients with h e r 2/neu 
overexpression receive trastuzumab, a monoclonal 
antibody against h e r 2/neu, concomitantly with pa-
clitaxel and r t.
The data concerning overexpression of the epi-
dermal growth factor receptor (e g f r) is conflicting. 
In surgical series, e g f r  has been adversely associated 
with prognosis 73, but in t m t  series from the r t o g , 
e g f r  expression appeared to correlate significantly 
with improved outcome 72.
Further work for bladder cancer patients is clearly 
needed in this exciting new molecular arena. Numer-
ous trials are currently ongoing, and hopefully this 
revolution in molecular and cellular biology will lead 
to higher cure rates.
6.  CONCLUSIONS
Bladder preservation therapy with t m t  is a safe treat-
ment that achieves survival rates similar to those 
achieved in modern cystectomy series; it should be 
considered an alternative first-line treatment for in-
vasive bladder cancer in selected patients. The 5- and 
10-year survival rates for muscle-invasive tumours 
are approximately 50% and 35%, comparable to the 
48% and 32% achievable with cystectomy 2. Approxi-
mately 80% of long-term survivors will preserve a 
native bladder, and approximately 75% of them will 
have a normal-functioning bladder.
The ideal candidate for bladder preservation 
therapy is a patient with a small tumour, stage T2, 
in whom a complete t u r b t  is achievable, who has no 
associated c i s or hydronephrosis, and who is medi-
cally fit to receive chemotherapy.
When a bladder preservation treatment is consid-
ered, the patient has to fully understand that there is 
a 1 in 3 chance of their requiring cystectomy at some 
point during treatment or follow-up, and that the sur-
vival rates described take into account cystectomy-
salvaged patients. Salvage is the reason that frequent 
follow-up with cystoscopy is a major component of 
any bladder preservation protocol.
Finally, the multidisciplinary cooperation of the 
urologist, the radiation oncologist, and the medical 
oncologist is of major importance—not only to de-
liver treatment in a timely manner, but also to actively 
follow the patient and to provide the earliest possible 
salvage treatment if needed.
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